Patent SG-11201908980P-A (SG)
Title: Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
Inventor: ROSSI JOHN
IPC: G01N33/50
Filed: 2018-04-03
Abstract: ANTICD CAR scFv (FMC63) HINGE/ TRANSMEMBRANE BLOOD CELLS REMOVED FROM PATIENT SIGNAL 2: CD28 GENETIC MODIFICATION OFT CELLS FIG. 1A SIGNAL 1: CD31; 4RE-INF6ON, CAR-T PRODUCT BIOMARKER PATIENT RECEIVES ANALYSIS CAR-T CELLS FIG. 1B CAR-T CELLS El 0 El 0 0 0 0 00 ▪ CO O 0 030 FIG. 1C K562-CD19 K562-NGFR (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT onolomolmomll Ammo oimIE (10) International Publication Number WO 2018/187332 Al N co C (51) International Patent Classification: A61K 39/00 (2006.01) GO1N 33/50 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/025888 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/481,003 03 April 2017 (03.04.2017) US (71) Applicant: KITE PHARMA, INC. [US/US]; 2225 Col- orado Avenue, Santa Monica, CA 90404 (US). (72) Inventors: ROSSI, John, M.; c/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404 (US). BOT, Adrian, I.; c/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404 (US). (74) Agent: BARBIC, Andrej et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: TREATMENT USING CHIMERIC RECEPTOR T CELLS INCORPORATING OPTIMIZED POLYFUNCTIONAL T = CELLS 1 -1 (57) : The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric re- ceptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of determining \" an effective dose of a T cell immunotherapy comprising polyfunctional T cells prior to administration to the patient. [Continued on next page] WO 2018/187332 Al MIDEDIMOHNOREEMOMOMINIMOIIIMEHOIMIE Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))